|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Huo Z, Gao Y, Yu Z, Zuo W and Zhang Y:
Metastasis of breast cancer to renal cancer: Report of a rare case.
Int J Clin Exp Pathol. 8:15417–15421. 2015.PubMed/NCBI
|
|
3
|
Oztas E, Kara H, Kara ZP, Aydogan MU, Uras
C and Ozhan G: Association between human telomerase reverse
transcriptase gene variations and risk of developing breast cancer.
Genet Test Mol Biomarkers. 20:459–464. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Siegel R, Miller K and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Takahashi M, Hayashida T, Okazaki H, Miyao
K, Jinno H and Kitagawa Y: Loss of B-cell translocation gene 2
expression in estrogen receptor-positive breast cancer predicts
tamoxifen resistance. Cancer Sci. 105:675–682. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gonzalez-Angulo AM, Morales-Vasquez F and
Hortobagyi GN: Overview of resistance to systemic therapy in
patients with breast cancer. Adv Exp Med Biol. 608:1–22. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Salomaa V, Havulinna A, Saarela O, Zeller
T, Jousilahti P, Jula A, Muenzel T, Aromaa A, Evans A, Kuulasmaa K
and Blankenberg S: Thirty-one novel biomarkers as predictors for
clinically incident diabetes. PLoS One. 5:e101002010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Robin X, Turck N, Hainard A, Tiberti N,
Lisacek F, Sanchez JC and Müller M: pROC: An open-source package
for R and S+ to analyze and compare ROC curves. BMC Bioinformatics.
12:772011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang Z: Too much covariates in a
multivariable model may cause the problem of overfitting. J Thorac
Dis. 6:E196–E197. 2014.PubMed/NCBI
|
|
10
|
Apuri S: Neoadjuvant and adjuvant
therapies for breast cancer. South Med J. 110:638–642. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Glassman D, Hignett S, Rehman S, Linforth
R and Salhab M: Adjuvant endocrine therapy for hormone-positive
breast cancer, focusing on ovarian suppression and extended
treatment: An update. Anticancer Res. 37:5329–5341. 2017.PubMed/NCBI
|
|
12
|
Gogalic S, Sauer U, Doppler S, Heinzel A,
Perco P, Lukas A, Simpson G, Pandha H, Horvath A and Preininger C:
Validation of a protein panel for the non-invasive detection of
recurrent non-muscle invasive bladder cancer. Biomarkers.
22:674–681. 2017.PubMed/NCBI
|
|
13
|
Urquidi V, Netherton M, Gomes-Giacoia E,
Serie DJ, Eckel-Passow J, Rosser CJ and Goodison S: A microRNA
biomarker panel for the non-invasive detection of bladder cancer.
Oncotarget. 7:86290–86299. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li Y, Huang J, Sun J, Xiang S, Yang D,
Ying X, Lu M, Li H and Ren G: The transcription levels and
prognostic values of seven proteasome alpha subunits in human
cancers. Oncotarget. 8:4501–4519. 2017.PubMed/NCBI
|
|
15
|
Kavalieris L, O'Sullivan P, Frampton C,
Guilford P, Darling D, Jacobson E, Suttie J, Raman JD, Shariat SF
and Lotan Y: Performance characteristics of a multigene urine
biomarker test for monitoring for recurrent urothelial carcinoma in
a multicenter study. J Urol. 197:1419–1426. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mihaly Z, Kormos M, Lanczky A, Dank M,
Budczies J, Szász MA and Győrffy B: A meta-analysis of gene
expression-based biomarkers predicting outcome after tamoxifen
treatment in breast cancer. Breast Cancer Res Treat. 140:219–232.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Slattery ML, Lundgreen A, Hines LM,
Torres-Mejia G, Wolff RK, Stern MC and John EM: Genetic variation
in the JAK/STAT/SOCS signaling pathway influences breast
cancer-specific mortality through interaction with cigarette
smoking and use of aspirin/NSAIDs: The breast cancer health
disparities study. Breast Cancer Res Treat. 147:145–158. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Papageorgis P, Ozturk S, Lambert AW,
Neophytou CM, Tzatsos A, Wong CK, Thiagalingam S and Constantinou
AI: Targeting IL13Ralpha2 activates STAT6-TP63 pathway to suppress
breast cancer lung metastasis. Breast Cancer Res. 17:982015.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hou S, Li N, Zhang Q, Li H, Wei X, Hao T,
Li Y, Azam S, Liu C, Cheng W, et al: XAB2 functions in mitotic cell
cycle progression via transcriptional regulation of CENPE. Cell
Death Dis. 7:e24092016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhao YF, Zhao JY, Yue H, Hu KS, Shen H,
Guo ZG and Su XJ: FOXD1 promotes breast cancer proliferation and
chemotherapeutic drug resistance by targeting p27. Biochem Biophys
Res Commun. 456:232–237. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sun T, Fu J, Shen T, Lin X, Liao L, Feng
XH and Xu J: The small c-terminal domain phosphatase 1 inhibits
cancer cell migration and invasion by dephosphorylating
ser(p)68-twist1 to accelerate twist1 protein degradation. J Biol
Chem. 291:11518–11528. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Miyamoto K, Fukutomi T, Akashi-Tanaka S,
Hasegawa T, Asahara T, Sugimura T and Ushijima T: Identification of
20 genes aberrantly methylated in human breast cancers. Int J
Cancer. 116:407–414. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gao T, Han Y, Yu L, Ao S, Li Z and Ji J:
CCNA2 is a prognostic biomarker for ER+ breast cancer and tamoxifen
resistance. PLoS One. 9:e917712014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Arigami T, Uenosono Y, Ishigami S,
Yanagita S, Hagihara T, Haraguchi N, Matsushita D, Hirahara T,
Okumura H, Uchikado Y, et al: Clinical significance of
stanniocalcin 2 expression as a predictor of tumor progression in
gastric cancer. Oncol Rep. 30:2838–2844. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jansen MP, Sas L, Sieuwerts AM, Van
Cauwenberghe C, Ramirez-Ardila D, Look M, Ruigrok-Ritstier K,
Finetti P, Bertucci F, Timmermans MM, et al: Decreased expression
of ABAT and STC2 hallmarks ER-positive inflammatory breast cancer
and endocrine therapy resistance in advanced disease. Mol Oncol.
9:1218–1233. 2015. View Article : Google Scholar : PubMed/NCBI
|
